Amphastar (AMPH) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$730.0M

Revenue (quarter)

$183.9M

Revenue growth (year over year)

+5.44%

Gross profit (trailing twelve months)

$348.1M

Gross margin

47.68%

Net income (trailing twelve months)

$78.5M

Net income (quarter)

$30.3M

Net income growth (year over year)

−2.20%

Net margin

10.76%

Return on equity

10.30%

EPS (trailing twelve months)

$1.74

Book value per share

$18.06

P/E (trailing twelve months)

14.31

Price to book

1.46

Debt to assets

55.95%

Payout ratio

—

Dividend yield

—

Company profile

Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.

• Is Amphastar (AMPH) profitable?

  Yes. Amphastar earned $78.5M in net income over the trailing twelve months, a net margin of 10.76%.

• How much revenue does Amphastar (AMPH) make?

  Amphastar generated $730.0M in revenue over the trailing twelve months, up 5.44% year over year.

• What is AMPH's P/E ratio?

  Amphastar trades at 14.3 times trailing twelve-month earnings, on an EPS of $1.74.

• How do I buy stock in Amphastar (AMPH)?

  AMPH trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.